How long should the patient stop taking Adderall (amphetamine/dextroamphetamine) before a Multiple Sleep Latency Test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinuation of Adderall Before MSLT

Patients should discontinue Adderall at least 2 weeks (14 days) before undergoing a Multiple Sleep Latency Test to ensure accurate diagnostic results.

Rationale and Evidence

The elimination half-life of amphetamine components in Adderall is critical to understanding the washout period. According to the FDA drug label, d-amphetamine has a mean elimination half-life of 9.77-11 hours, while l-amphetamine has a half-life of 11.5-13.8 hours 1. However, the standard pharmacological principle of waiting 5 half-lives for complete drug elimination translates to approximately 3 days for the drug itself to clear.

Why 2 Weeks Is Necessary

The 2-week recommendation extends beyond simple pharmacokinetic elimination for several important reasons:

  • Active metabolites: Amphetamine undergoes metabolism to form active compounds including 4-hydroxyamphetamine and norephedrine, which can continue to affect CNS function 1

  • Neuroadaptive changes: Chronic amphetamine use causes alterations in dopamine and norepinephrine systems that require time to normalize beyond simple drug clearance 1

  • MSLT validity: The MSLT measures objective sleepiness, and stimulants directly counteract this by promoting wakefulness. Even subtle residual effects can mask true hypersomnolence and lead to false-negative results 2, 3

Clinical Context and Monitoring

Pre-Test Preparation

The 2024 AASM pediatric MSLT guidance emphasizes comprehensive patient preparation, though it does not specify exact washout periods for individual medications 3. The 2021 adult MSLT protocol similarly stresses the importance of medication evaluation but defers to clinical judgment 2.

Key preparation steps:

  • Document all medications, including dose and duration of Adderall use
  • Consider actigraphy for 7-14 days before testing to monitor sleep-wake patterns and ensure adequate sleep time 4
  • Ensure minimum 7 hours of sleep (8-hour recording time) on polysomnography the night before MSLT 3

Urinary Drug Screening

Perform urine drug screening on the morning of the MSLT to confirm amphetamine clearance. Research demonstrates that 16% of patients undergoing MSLT have positive drug screens for undisclosed substances, including amphetamines 5. Amphetamine can be detected in urine for 1-75% of the dose depending on urinary pH, with detection possible for several days after discontinuation 1.

Important Caveats

  • Methylphenidate does not cross-react with amphetamine immunoassays, so standard urine drug screens will not detect it 6
  • pH-dependent elimination: Alkaline urine reduces amphetamine excretion and may prolong detection times 1, 7
  • Individual variability: Factors including renal function, urinary pH, and genetic polymorphisms in CYP2D6 can affect elimination rates 1

Risk of Inadequate Washout

Insufficient washout periods can lead to:

  • False-negative MSLT results: Residual stimulant effects may mask pathological sleepiness, preventing accurate diagnosis of narcolepsy or idiopathic hypersomnia 5
  • Misdiagnosis: Patients with true central disorders of hypersomnolence may be incorrectly classified as having normal sleep latency
  • Treatment delays: Inaccurate testing necessitates repeat studies after proper medication discontinuation

Special Considerations

For patients who cannot safely discontinue Adderall for 2 weeks due to severe ADHD symptoms affecting safety (e.g., occupational drivers, those with significant functional impairment), shared decision-making is essential. Options include:

  • Postponing MSLT until a safer time for medication discontinuation
  • Accepting potential test limitations with documented informed consent
  • Considering alternative diagnostic approaches in consultation with sleep medicine specialists

The 2-week washout period represents a conservative, evidence-based approach that balances pharmacokinetic principles with the clinical reality of neuroadaptive changes, ensuring the highest diagnostic accuracy for the MSLT.

References

Research

Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2021

Research

Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in children: guidance from the American Academy of Sleep Medicine.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2024

Guideline

use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Research

Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and Maintenance of Wakefulness Test.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2016

Guideline

prescribing controlled substances in sleep medicine clinics: an overview of legal issues and best safety practices.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.